

Continuation of bevacizumab after first progression in (ML18147): a randomised phase 3 trial

Lancet Oncology, The

14, 29-37

DOI: [10.1016/s1470-2045\(12\)70477-1](https://doi.org/10.1016/s1470-2045(12)70477-1)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Systemic chemotherapy for hepatic colorectal cancer. , 2012, , 1434-1443.e3. | | 0 |
| 2 | Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept. <i>Biologics in Therapy</i> , 2013, 3, 25-33. | 1.8 | 8 |
| 3 | Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 869-871. | 1.5 | 8 |
| 4 | Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 131, 241-245. | 0.6 | 27 |
| 5 | An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic Colorectal cancer Treated with bevacizumab (Avastin) [ASCENT]. <i>BMC Cancer</i> , 2013, 13, 120. | 1.1 | 18 |
| 6 | Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. <i>British Journal of Cancer</i> , 2013, 109, 1408-1413. | 2.9 | 15 |
| 7 | SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 996-1003. | 1.2 | 20 |
| 8 | The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 230-241. | 1.0 | 2 |
| 9 | Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 213-222. | 1.0 | 1 |
| 10 | The role of maintenance therapy in metastatic colorectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 144-146. | 0.3 | 0 |
| 11 | Drug rechallenge and treatment beyond progression—implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 571-587. | 12.5 | 219 |
| 12 | Influence of tumour micro-environment heterogeneity on therapeutic response. <i>Nature</i> , 2013, 501, 346-354. | 13.7 | 2,093 |
| 13 | A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2013, 109, 1725-1734. | 2.9 | 38 |
| 14 | Rechallenge of drugs in the era of targeted therapy. <i>Lancet Oncology</i> , The, 2013, 14, 1143-1145. | 5.1 | 5 |
| 15 | Maintenance Therapy for Advanced Lung Cancer: Who, What, and When?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2983-2990. | 0.8 | 13 |
| 16 | Safety of Bevacizumab in Treating Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis of All Randomized Clinical Trials. <i>Clinical Drug Investigation</i> , 2013, 33, 779-788. | 1.1 | 30 |
| 17 | Efficacy and Safety of Aflibercept and Its Role in the Treatment of Metastatic Colorectal Cancer. <i>Rare Cancers and Therapy</i> , 2013, 1, 3-19. | 0.2 | 2 |
| 18 | Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 92. | 3.5 | 77 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1077-1085. | 5.1 | 550 |
| 20 | Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2203-2220. | 0.9 | 4 |
| 21 | Hypercastration in prostate cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 303-305. | 1.2 | 1 |
| 22 | Paradigme de la prise en charge du cancer bronchique et de celle des autres cancers : homologues, analogies, dissemblances. <i>Revue Des Maladies Respiratoires Actualites</i> , 2013, 5, 562-571. | 0.0 | 0 |
| 23 | Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study. <i>Clinical Colorectal Cancer</i> , 2013, 12, 239-247. | 1.0 | 28 |
| 24 | How we treat metastatic colon cancer in older adults. <i>Journal of Geriatric Oncology</i> , 2013, 4, 295-301. | 0.5 | 11 |
| 25 | A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). <i>European Journal of Cancer</i> , 2013, 49, 3507-3516. | 1.3 | 21 |
| 26 | Will PICCOLO affect metastatic colorectal cancer therapy?. <i>Lancet Oncology</i> , The, 2013, 14, 679-680. | 5.1 | 0 |
| 27 | Role of targeted agents in metastatic colorectal cancer. <i>Targeted Oncology</i> , 2013, 8, 83-96. | 1.7 | 58 |
| 28 | Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. <i>Investigational New Drugs</i> , 2013, 31, 1035-1043. | 1.2 | 12 |
| 29 | Current opinion on optimal treatment for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 597-611. | 1.1 | 30 |
| 30 | Update on bevacizumab and other angiogenesis inhibitors for brain cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 137-153. | 1.0 | 29 |
| 31 | Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 749-759. | 5.1 | 333 |
| 32 | New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy. <i>Drugs</i> , 2013, 73, 883-891. | 4.9 | 22 |
| 34 | Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). <i>Journal of Medical Economics</i> , 2013, 16, 1387-1398. | 1.0 | 30 |
| 35 | Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1489-1493. | 1.4 | 2 |
| 36 | Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 317-325. | 1.0 | 2 |
| 37 | Molecular therapies of colorectal cancer: where will we go from here?. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 215-219. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 38 | A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OCGS1203 (HERBIS-5). <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 838-840. | 0.6 | 15 |
| 39 | Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. <i>Annals of Oncology</i> , 2013, 24, 2342-2349. | 0.6 | 89 |
| 42 | Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. <i>Onkologie</i> , 2013, 36, 363-367. | 1.1 | 3 |
| 43 | Bevacizumab-Based Therapy for Colorectal Cancer: Experience from a Large Canadian Cohort at the Jewish General Hospital between 2004 and 2009. <i>Current Oncology</i> , 2013, 20, 247-251. | 0.9 | 6 |
| 44 | A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. <i>Annals of Oncology</i> , 2013, 24, 2335-2341. | 0.6 | 68 |
| 45 | Bevacizumab for Glioblastoma—A Promising Drug or Not?. <i>Cancers</i> , 2013, 5, 1456-1468. | 1.7 | 4 |
| 46 | Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials. <i>Oncologist</i> , 2013, 18, 1004-1012. | 1.9 | 210 |
| 47 | Phase I/II Trial of Irinotecan and S-1 Combination Chemotherapy as a Second-Line Treatment for Advanced Colorectal Cancer. <i>Chemotherapy</i> , 2013, 59, 338-343. | 0.8 | 2 |
| 48 | Oxaliplatin for colorectal cancer: recent evidence from clinical trials. <i>Colorectal Cancer</i> , 2013, 2, 135-144. | 0.8 | 1 |
| 49 | Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer. <i>Chemotherapy</i> , 2013, 59, 79-84. | 0.8 | 2 |
| 50 | Ziv-aflibercept in metastatic colorectal cancer. <i>Biologics: Targets and Therapy</i> , 2013, 8, 13. | 3.0 | 30 |
| 51 | Aflibercept. <i>Clinical Cancer Research</i> , 2013, 19, 1920-1925. | 3.2 | 92 |
| 52 | Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type <i>KRAS</i> . <i>Cancer Science</i> , 2013, 104, 473-480. | 1.7 | 6 |
| 53 | Developing a national database for metastatic colorectal cancer management: perspectives and challenges. <i>Internal Medicine Journal</i> , 2013, 43, 1224-1231. | 0.5 | 33 |
| 54 | Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. <i>Pharmacological Reviews</i> , 2013, 65, 1351-1395. | 7.1 | 33 |
| 55 | HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy?. <i>British Journal of Cancer</i> , 2013, 108, 477-478. | 2.9 | 3 |
| 57 | Sequencing of Treatment in Advanced Unresectable Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-28-S-37. | 2.3 | 3 |
| 58 | Emerging Treatments in Recurrent and Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-18-S-27. | 2.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 59 | A Long-Term Survival Case of Rectal Cancer With Multiple Pulmonary Metastases Treated With Multidisciplinary Chemotherapy. <i>International Surgery</i> , 2013, 98, 311-314. | 0.0 | 1 |
| 60 | Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 3190-3200. | 3.9 | 527 |
| 61 | Systemic Therapy for Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 649-652. | 2.3 | 9 |
| 62 | Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). <i>Cancer Management and Research</i> , 2013, 5, 377. | 0.9 | 10 |
| 63 | Molecularly targeted drugs for metastatic colorectal cancer. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1315. | 2.0 | 38 |
| 64 | Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. <i>OncoTargets and Therapy</i> , 2013, 6, 1761. | 1.0 | 7 |
| 65 | Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab. <i>PLoS ONE</i> , 2013, 8, e66774. | 1.1 | 64 |
| 66 | Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy. <i>PLoS ONE</i> , 2014, 9, e84940. | 1.1 | 40 |
| 67 | Hepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era. <i>Current Oncology</i> , 2014, 21, 116. | 0.9 | 35 |
| 68 | A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. <i>OncoTargets and Therapy</i> , 2014, 7, 1177. | 1.0 | 2 |
| 69 | Advances and new perspectives in the treatment of metastatic colon cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2014, 6, 211. | 0.8 | 25 |
| 70 | Anti-angiogenesis in prostate cancer: knocked down but not out. <i>Asian Journal of Andrology</i> , 2014, 16, 372. | 0.8 | 20 |
| 71 | XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI. <i>Molecular and Clinical Oncology</i> , 2014, 2, 827-832. | 0.4 | 4 |
| 72 | Targeting metastatic colorectal cancer – present and emerging treatment options. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 137. | 0.4 | 14 |
| 73 | Management of locally advanced and metastatic colon cancer in elderly patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 1910. | 1.4 | 17 |
| 74 | 90Y Radioembolization. <i>Oncology Issues</i> , 2014, 29, 46-52. | 0.0 | 0 |
| 75 | Sequencing of treatment in metastatic colorectal cancer: Where to fit the target. <i>World Journal of Gastroenterology</i> , 2014, 20, 1993. | 1.4 | 23 |
| 78 | Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27048. | 2.1 | 69 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 79 | Anti-angiogenic agent ramucirumab: meaningful or marginal?. Expert Review of Anticancer Therapy, 2014, 14, 367-379. | 1.1 | 12 |
| 80 | Regorafenib in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2014, 14, 255-265. | 1.1 | 20 |
| 81 | Therapeutic targeting of tumor angiogenesis: how far have we come?. Clinical Investigation, 2014, 4, 1113-1122. | 0.0 | 0 |
| 82 | Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. Future Oncology, 2014, 10, 1137-1145. | 1.1 | 16 |
| 83 | Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?. Future Oncology, 2014, 10, 149-152. | 1.1 | 0 |
| 84 | Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept. Gastroenterology Research and Practice, 2014, 2014, 1-13. | 0.7 | 44 |
| 85 | Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials. Gastroenterology Research and Practice, 2014, 2014, 1-8. | 0.7 | 19 |
| 86 | Moguntinonesâ€”New Selective Inhibitors for the Treatment of Human Colorectal Cancer. Molecular Cancer Therapeutics, 2014, 13, 1399-1409. | 1.9 | 5 |
| 87 | Immunotherapy for Gastrointestinal Malignancies. Journal of Cancer Therapy, 2014, 05, 622-646. | 0.1 | 0 |
| 88 | Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. Hepatic Oncology, 2014, 1, 331-345. | 4.2 | 0 |
| 89 | Bevacizumab in the treatment of epithelial ovarian carcinoma. Clinical Investigation, 2014, 4, 535-548. | 0.0 | 0 |
| 90 | How can we manage resistance to antiangiogenic drugs?. Clinical Investigation, 2014, 4, 483-486. | 0.0 | 0 |
| 91 | Biologic agents in the treatment of colorectal cancer: an update. Colorectal Cancer, 2014, 3, 363-374. | 0.8 | 1 |
| 92 | Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2014, 106, djt371-djt371. | 3.0 | 87 |
| 93 | Does the type of firstâ€”line regimens influence the receipt of secondâ€”line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Medicine, 2014, 3, 124-133. | 1.3 | 5 |
| 94 | FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer. Oncology, 2014, 87, 148-158. | 0.9 | 15 |
| 95 | Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncology, The, 2014, 15, 1481-1492. | 5.1 | 139 |
| 96 | Chemotherapyâ€”induced peripheral neurotoxicity (<scp>CIPN</scp>): what we need and what we know. Journal of the Peripheral Nervous System, 2014, 19, 66-76. | 1.4 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 97 | Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Review of Anticancer Therapy, 2014, 14, 1477-1493. | 1.1 | 12 |
| 98 | Optimal duration of systemic treatment in metastatic colorectal cancer. Current Opinion in Oncology, 2014, 26, 448-453. | 1.1 | 9 |
| 99 | From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors. Tumor Biology, 2014, 35, 8471-8482. | 0.8 | 3 |
| 101 | Unintended Consequences of Expensive Cancer Therapeuticsâ€”The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 1225. | 1.2 | 263 |
| 102 | Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. OncoTargets and Therapy, 2014, 7, 1415. | 1.0 | 25 |
| 103 | Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 322-329. | 0.7 | 10 |
| 104 | Biomarkers and Response to Bevacizumabâ€”Letter. Clinical Cancer Research, 2014, 20, 1056-1057. | 3.2 | 8 |
| 105 | Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement. Future Oncology, 2014, 10, 2643-2657. | 1.1 | 6 |
| 106 | Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the AvastinÂ® Registry â€” Investigation of Effectiveness and Safety (ARIES) Observational Cohort Study. Clinical Oncology, 2014, 26, 323-332. | 0.6 | 30 |
| 107 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial. European Journal of Cancer, 2014, 50, 320-331. | 1.3 | 211 |
| 108 | Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection. Annals of Surgical Oncology, 2014, 21, 1632-1640. | 0.7 | 23 |
| 109 | Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab. Clinical and Translational Oncology, 2014, 16, 739-745. | 1.2 | 18 |
| 110 | A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. Journal of Cancer Research and Clinical Oncology, 2014, 140, 537-547. | 1.2 | 85 |
| 111 | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis, 2014, 17, 471-494. | 3.7 | 626 |
| 112 | Genetic markers of bevacizumab-induced hypertension. Angiogenesis, 2014, 17, 685-94. | 3.7 | 24 |
| 113 | Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. Journal of Neuro-Oncology, 2014, 117, 85-92. | 1.4 | 11 |
| 115 | Discrete Improvement in Racial Disparity in Survival among Patients with Stage IV Colorectal Cancer: a 21-Year Population-Based Analysis. Journal of Gastrointestinal Surgery, 2014, 18, 1194-1204. | 0.9 | 18 |
| 116 | The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis, 2014, 17, 805-821. | 3.7 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 117 | Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?. Current Oncology Reports, 2014, 16, 363. | 1.8 | 9 |
| 118 | Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 76-82. | 0.8 | 148 |
| 119 | Methods of overcoming treatment resistance in colorectal cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 217-230. | 2.0 | 58 |
| 120 | HER2-positive gastric cancer. Gastric Cancer, 2014, 17, 1-12. | 2.7 | 272 |
| 121 | Towards improved drugs, combinations and patient selection. Nature Reviews Clinical Oncology, 2014, 11, 79-80. | 12.5 | 49 |
| 122 | Bevacizumab: A Review of Its Use in Advanced Cancer. Drugs, 2014, 74, 1891-1925. | 4.9 | 142 |
| 123 | Ziv-aflibercept (Zaltrap) for the Treatment of Metastatic Colorectal Cancer. Annals of Pharmacotherapy, 2014, 48, 93-98. | 0.9 | 16 |
| 124 | Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 219-225. | 1.0 | 35 |
| 125 | New Targets and New Drug Development in Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 288-295. | 1.0 | 1 |
| 126 | Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiology and Drug Safety, 2014, 23, 726-734. | 0.9 | 43 |
| 127 | Navigating later lines of treatment for advanced colorectal cancer – Optimizing targeted biological therapies to improve outcomes. Cancer Treatment Reviews, 2014, 40, 1171-1181. | 3.4 | 18 |
| 128 | The role of targeted therapy for gastrointestinal tumors. Expert Review of Gastroenterology and Hepatology, 2014, 8, 875-885. | 1.4 | 27 |
| 129 | Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii1-iii9. | 0.6 | 910 |
| 130 | Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data. Oncologist, 2014, 19, 1156-1168. | 1.9 | 90 |
| 131 | Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1269-1278. | 5.1 | 118 |
| 132 | Metastatic Colorectal Cancer Treatment Patterns According to Kirsten Rat Sarcoma Viral Oncogene Homolog Genotype in U.S. Community-Based Oncology Practices. Clinical Colorectal Cancer, 2014, 13, 178-184. | 1.0 | 4 |
| 133 | Advances in the management of colorectal cancer: from biology to treatment. International Journal of Colorectal Disease, 2014, 29, 1031-1042. | 1.0 | 75 |
| 134 | The ‘œangiogenetic ladder’, step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treatment Reviews, 2014, 40, 934-941. | 3.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 135 | Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308. | 1.3 | 32 |
| 136 | The Challenge to Optimize Medical Therapy for Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt442-djt442. | 3.0 | 1 |
| 137 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1065-1075. | 5.1 | 1,479 |
| 138 | How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 743-748. | 1.4 | 15 |
| 140 | Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 893-906. | 0.8 | 49 |
| 141 | Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics. <i>Oncologie</i> , 2014, 16, 267-276. | 0.2 | 2 |
| 142 | Clinical End Points and Relevant Clinical Benefits in Advanced Colorectal Cancer Trials. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 254-262. | 1.0 | 0 |
| 144 | Aflibercept – a Decoy VEGF Receptor. <i>Current Oncology Reports</i> , 2014, 16, 368. | 1.8 | 56 |
| 145 | Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1051-1061. | 1.1 | 3 |
| 146 | Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1351-1360. | 5.1 | 120 |
| 147 | Bevacizumab beyond progression in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, 1190-1191. | 5.1 | 2 |
| 149 | Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: A clinician's perspective. <i>Cancer Treatment Reviews</i> , 2014, 40, 1065-1072. | 3.4 | 15 |
| 150 | The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. <i>British Journal of Cancer</i> , 2014, 111, 1122-1131. | 2.9 | 28 |
| 151 | Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 9-34. | 2.0 | 27 |
| 152 | Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1302-1308. | 0.8 | 1,240 |
| 153 | Sequencing of Antiangiogenic Agents in the Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 135-144. | 1.0 | 27 |
| 154 | Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond. <i>Seminars in Oncology</i> , 2014, 41, 235-251. | 0.8 | 129 |
| 155 | Options for metastatic colorectal cancer beyond the second line of treatment. <i>Digestive and Liver Disease</i> , 2014, 46, 105-112. | 0.4 | 42 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 156 | Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US. <i>Journal of Cancer Policy</i> , 2014, 2, 1-11. | 0.6 | 48 |
| 157 | Bevacizumab in Non-small Cell Lung Cancer: An Overview of Practice in the Era of Molecular Testing. <i>Clinical Oncology</i> , 2014, 26, 468-472. | 0.6 | 3 |
| 158 | Management of colorectal cancer. <i>F1000prime Reports</i> , 2014, 6, 108. | 5.9 | 86 |
| 159 | Colon Cancer, Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1028-1059. | 2.3 | 192 |
| 160 | SIR-Spheres [®] radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. <i>Colorectal Cancer</i> , 2014, 3, 331-343. | 0.8 | 0 |
| 161 | Maintenance treatment for metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 501-509. | 0.8 | 0 |
| 163 | Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1097-1101. | 2.3 | 11 |
| 166 | Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice. <i>Journal of Hematology and Oncology</i> , 2015, 8, 92. | 6.9 | 17 |
| 167 | Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. <i>BMC Cancer</i> , 2015, 15, 643. | 1.1 | 23 |
| 168 | Thromboembolic Disease in Advanced Colorectal Cancer Treated with Chemotherapy and Bevacizumab: A Case of Real “Pan-Thrombosis”. <i>Tumori</i> , 2015, 101, e32-e33. | 0.6 | 1 |
| 169 | Three-Dimensional Ultrasound Molecular Imaging of Angiogenesis in Colon Cancer Using a Clinical Matrix Array Ultrasound Transducer. <i>Investigative Radiology</i> , 2015, 50, 322-329. | 3.5 | 43 |
| 170 | Systemic Treatment: Maintenance Compared with Holiday. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 85-90. | 1.8 | 3 |
| 171 | Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. <i>Ecancermedicalsecience</i> , 2015, 9, 582. | 0.6 | 7 |
| 172 | Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. <i>Clinical Interventions in Aging</i> , 2015, 10, 127. | 1.3 | 2 |
| 173 | The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 835. | 1.0 | 22 |
| 174 | Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 2407. | 1.0 | 10 |
| 175 | Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab. <i>OncoTargets and Therapy</i> , 2015, 8, 2005. | 1.0 | 3 |
| 176 | Biologic Therapies in Colorectal Cancer: Indications and Contraindications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e197-e206. | 1.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 177 | Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 68-77. | 1.0 | 4 |
| 178 | A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1653. | 2.0 | 7 |
| 179 | Profile of bevacizumab and its potential in the treatment of cervical cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 3425. | 1.0 | 4 |
| 180 | Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2015, 21, 5072. | 1.4 | 59 |
| 181 | Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0136324. | 1.1 | 25 |
| 182 | Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. <i>PLoS ONE</i> , 2015, 10, e0135599. | 1.1 | 22 |
| 183 | Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials. <i>OncoTargets and Therapy</i> , 2015, 8, 2775. | 1.0 | 8 |
| 184 | RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data. <i>Current Treatment Options in Oncology</i> , 2015, 16, 33. | 1.3 | 2 |
| 185 | Unraveling the Complexities of Treating Metastatic Colorectal Cancer With Angiogenesis Inhibitors. <i>Clinical Colorectal Cancer</i> , 2015, 14, 131-132. | 1.0 | 1 |
| 186 | Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 155-162. | 1.4 | 27 |
| 187 | Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 995-1004. | 1.5 | 3 |
| 188 | Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 243. | 1.0 | 1 |
| 189 | EGFR signaling in colorectal cancer: a clinical perspective. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 0, , 21. | 5.5 | 10 |
| 190 | SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 972-981. | 1.2 | 26 |
| 191 | Potent antitumor activity of cabozantinib, a MET and VEGFR_2 inhibitor, in a colorectal cancer patient-derived tumor explant model. <i>International Journal of Cancer</i> , 2015, 136, 1967-1975. | 2.3 | 47 |
| 192 | 203P A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGS1203 (HERBIS-5). <i>Annals of Oncology</i> , 2015, 26, ix42. | 0.6 | 0 |
| 193 | Update on Anti-angiogenesis Therapy in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 378-387. | 1.0 | 9 |
| 194 | Inhibitors of Angiogenesis. , 2015, , 261-285. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 195 | Protein Targeting Compounds. , 2015, , . | | 1 |
| 196 | Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial. <i>Clinical Investigation</i> , 2015, 5, 665-675. | 0.0 | 1 |
| 197 | New hope on the horizon for patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2015, 4, 229-239. | 0.8 | 0 |
| 198 | Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. <i>Targeted Oncology</i> , 2015, 10, 199-213. | 1.7 | 46 |
| 199 | Bevacizumab: A dose review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 311-322. | 2.0 | 32 |
| 200 | Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 129-143. | 0.8 | 14 |
| 201 | Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). <i>Annals of Oncology</i> , 2015, 26, 709-714. | 0.6 | 119 |
| 202 | Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043. | 3.2 | 31 |
| 203 | Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. <i>Digestive and Liver Disease</i> , 2015, 47, 331-337. | 0.4 | 23 |
| 204 | Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 515-522. | 1.2 | 10 |
| 205 | Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015, 26, 724-730. | 0.6 | 136 |
| 206 | SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 72-80. | 1.0 | 98 |
| 208 | Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 153-169. | 1.4 | 50 |
| 209 | First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United Statesâ€‘Based Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1112-1118. | 0.8 | 144 |
| 210 | Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. <i>European Journal of Cancer</i> , 2015, 51, 18-26. | 1.3 | 21 |
| 211 | Current controversies in the management of metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 659-677. | 1.1 | 17 |
| 212 | Aflibercept: A Review in Metastatic Colorectal Cancer. <i>Drugs</i> , 2015, 75, 1435-1445. | 4.9 | 32 |
| 213 | Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 323-336. | 2.0 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 214 | The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1359-1370. | 1.4 | 13 |
| 215 | Aflibercept a new target therapy in cancer treatment: a review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 569-576. | 2.0 | 24 |
| 216 | Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials. <i>Acta Oncologica</i> , 2015, 54, 187-193. | 0.8 | 16 |
| 217 | Improved Outcomes in Metastatic Colon Cancer. <i>JAMA Oncology</i> , 2015, 1, 795. | 3.4 | 4 |
| 218 | Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 928-936. | 5.1 | 661 |
| 219 | A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). <i>Lung Cancer</i> , 2015, 89, 146-153. | 0.9 | 16 |
| 220 | The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1205-1220. | 1.4 | 19 |
| 221 | The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2015, 7, 439-449. | 1.7 | 2 |
| 222 | Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2015, 51, 1231-1242. | 1.3 | 68 |
| 223 | Always look at the bright side of drugs?. <i>Acta Oncologica</i> , 2015, 54, 145-147. | 0.8 | 2 |
| 224 | When less is more: maintenance therapy in colorectal cancer. <i>Lancet</i> , The, 2015, 385, 1808-1810. | 6.3 | 13 |
| 225 | Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 273-276. | 1.4 | 11 |
| 226 | Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 286-290. | 0.6 | 9 |
| 227 | Metastatic Colorectal Cancer: Current State and Future Directions. <i>Journal of Clinical Oncology</i> , 2015, 33, 1809-1824. | 0.8 | 418 |
| 228 | Second-line therapy for metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, 476-477. | 5.1 | 0 |
| 229 | Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 499-508. | 5.1 | 753 |
| 231 | Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 993-1004. | 1.1 | 12 |
| 232 | Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?. <i>Supportive Care in Cancer</i> , 2015, 23, 1623-1627. | 1.0 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 234 | Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 935-942. | 1.0 | 9 |
| 235 | Immunotherapeutic Strategies for Colon Cancer: Monoclonal Antibody Therapy. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 84-91. | 1.0 | 1 |
| 237 | A single-arm clinical study of continuous usage of bevacizumab as second-line chemotherapy for Chinese patients with metastatic colorectal cancer. <i>Medical Oncology</i> , 2015, 32, 163. | 1.2 | 4 |
| 238 | Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). <i>BMC Cancer</i> , 2015, 15, 176. | 1.1 | 2 |
| 239 | FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. <i>Annals of Oncology</i> , 2015, 26, 1427-1433. | 0.6 | 45 |
| 240 | The Expanding Role of Therapeutic Antibodies. <i>International Reviews of Immunology</i> , 2015, 34, 202-264. | 1.5 | 22 |
| 241 | Liver transplantation in treatment of colorectal liver metastases. <i>Hepatic Oncology</i> , 2015, 2, 181-190. | 4.2 | 7 |
| 242 | Perfusion CT imaging of treatment response in oncology. <i>European Journal of Radiology</i> , 2015, 84, 2380-2385. | 1.2 | 46 |
| 243 | Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Español Multidisciplinar en Cancer Digestivo (GEMCAD). <i>Colorectal Cancer</i> , 2015, 4, 97-112. | 0.8 | 0 |
| 244 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 207-239. | 1.0 | 548 |
| 245 | Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 408-410. | 0.6 | 17 |
| 246 | Incorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 18. | 1.3 | 11 |
| 247 | Progression-Free Survival: Helpful Biomarker or Clinically Meaningless End Point?. <i>Journal of Clinical Oncology</i> , 2015, 33, 4-6. | 0.8 | 40 |
| 248 | Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. <i>Lancet</i> , The, 2015, 385, 1843-1852. | 6.3 | 421 |
| 250 | First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405. <i>Current Treatment Options in Oncology</i> , 2015, 16, 52. | 1.3 | 66 |
| 251 | Three-dimensional Dynamic Contrast-enhanced US Imaging for Early Antiangiogenic Treatment Assessment in a Mouse Colon Cancer Model. <i>Radiology</i> , 2015, 277, 424-434. | 3.6 | 32 |
| 252 | Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1493-1505. | 5.1 | 106 |
| 253 | Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. <i>BMC Cancer</i> , 2015, 15, 327. | 1.1 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 254 | STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 496. | 1.1 | 20 |
| 255 | A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 601. | 1.1 | 13 |
| 256 | Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 41. | 1.3 | 8 |
| 257 | Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study. <i>Cancer Biology and Therapy</i> , 2015, 16, 1577-1584. | 1.5 | 16 |
| 258 | Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. <i>Medical Oncology</i> , 2015, 32, 469. | 1.2 | 9 |
| 259 | A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573. | 0.6 | 635 |
| 260 | How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). <i>Current Colorectal Cancer Reports</i> , 2015, 11, 151-159. | 1.0 | 2 |
| 261 | Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumors in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3718-3726. | 0.8 | 112 |
| 262 | Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?. <i>Oncologist</i> , 2015, 20, 981-982. | 1.9 | 26 |
| 263 | An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1307-1320. | 1.9 | 7 |
| 264 | Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3727-3732. | 0.8 | 86 |
| 265 | Maintenance therapy for metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, 1281-1282. | 5.1 | 2 |
| 266 | Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. <i>British Journal of Cancer</i> , 2015, 113, 1027-1034. | 2.9 | 34 |
| 267 | Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project. <i>Oncology</i> , 2015, 88, 103-121. | 0.9 | 9 |
| 268 | Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis. <i>Investigational New Drugs</i> , 2015, 33, 1144-1147. | 1.2 | 10 |
| 269 | Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1171-1179. | 1.0 | 8 |
| 270 | Bevacizumab beyond first disease progression in metastatic colorectal cancer: a review of recent clinical trial data. <i>Colorectal Cancer</i> , 2015, 4, 13-25. | 0.8 | 0 |
| 271 | Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 195-205. | 2.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 272 | Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3686-3688. | 0.8 | 16 |
| 274 | Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 154-160. | 0.9 | 53 |
| 275 | Is More Not Better?. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 85-116. | 0.9 | 3 |
| 276 | Gemcitabine plus capecitabine (Gem+Cap) biweekly in chemorefractory metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2015, 17, 384-392. | 1.2 | 13 |
| 277 | Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC). <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 43-60. | 0.9 | 24 |
| 278 | Recent Therapeutic Advances in the Treatment of Colorectal Cancer. <i>Annual Review of Medicine</i> , 2015, 66, 83-95. | 5.0 | 162 |
| 279 | Integrating Systemic and Surgical Approaches to Treating Metastatic Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 199-214. | 0.6 | 7 |
| 280 | Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 45-59. | 1.4 | 8 |
| 281 | Progression Pattern and Adverse Events with Bevacizumab in Glioblastoma. <i>Current Oncology</i> , 2016, 23, 468-471. | 0.9 | 8 |
| 282 | BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2016, 29, 173-179. | 0.5 | 7 |
| 283 | Antibody Therapy. , 2016, , 550-559. | | 2 |
| 284 | Role of targeted therapy in metastatic colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 642. | 0.8 | 80 |
| 285 | Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-oesophageal junction adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4539-4548. | 1.0 | 3 |
| 286 | Targeting Tumor Angiogenesis in Gastrointestinal Malignancies. <i>Current Angiogenesis</i> , 2016, 4, 37-45. | 0.1 | 0 |
| 287 | The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2016, 7, 1901-1906. | 1.2 | 5 |
| 288 | Tumor refractoriness to anti-VEGF therapy. <i>Oncotarget</i> , 2016, 7, 46668-46677. | 0.8 | 81 |
| 289 | Role of Biologics in First-Line Treatment of Colorectal Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1219-1228. | 2.5 | 32 |
| 290 | Targeting angiogenesis in gastrointestinal tumors: current challenges. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 67-67. | 1.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 291 | RAS and BRAF in metastatic colorectal cancer management. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 687-704. | 0.6 | 56 |
| 292 | Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 34811-34823. | 0.8 | 43 |
| 293 | Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. <i>Oncology Letters</i> , 2016, 12, 3127-3134. | 0.8 | 2 |
| 294 | Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. <i>BioMed Research International</i> , 2016, 2016, 1-14. | 0.9 | 19 |
| 295 | Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. <i>OncoTargets and Therapy</i> , 2016, 9, 1899. | 1.0 | 44 |
| 297 | Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2016, Volume 6, 21-30. | 5.5 | 8 |
| 298 | Successful Multidisciplinary Treatment with Secondary Metastatic Liver Resection after Downsizing by Palliative Second-Line Treatment of Colorectal Cancer: A Curative Option. <i>Case Reports in Oncology</i> , 2016, 9, 379-386. | 0.3 | 1 |
| 299 | Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. <i>International Journal of Women's Health</i> , 2016, 8, 59. | 1.1 | 27 |
| 300 | Molecular-targeted Therapies in Gastrointestinal Cancer. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2016, 105, 1051-1060. | 0.0 | 0 |
| 301 | Evidence-based Clinical Management of Acute Malignant Colorectal Obstruction. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 273-285. | 1.1 | 43 |
| 302 | Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of first-line or second-line systemic chemotherapy. <i>Anti-Cancer Drugs</i> , 2016, 27, 118-126. | 0.7 | 6 |
| 303 | A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 501-507. | 1.1 | 9 |
| 304 | Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (Wrest) Trial. <i>Cancer</i> , 2016, 122, 1050-1059. | 2.0 | 35 |
| 305 | Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. <i>Supportive Care in Cancer</i> , 2016, 24, 4057-4074. | 1.0 | 21 |
| 306 | Maintenance based Bevacizumab versus complete stop or continuous therapy after induction therapy in first line treatment of stage IV colorectal cancer: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 115-123. | 2.0 | 12 |
| 307 | Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small cell lung cancer: analyses of the ARIES observational cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 569-577. | 0.9 | 2 |
| 308 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422. | 0.6 | 2,545 |
| 309 | Bevacizumab beyond disease progression for advanced non-small cell lung cancer: Does persistence have its rewards?. <i>Cancer</i> , 2016, 122, 1047-1049. | 2.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 310 | Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C ³) study. <i>BMJ Open</i> , 2016, 6, e011454. | 0.8 | 6 |
| 311 | A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study). <i>Oncology</i> , 2016, 91, 24-30. | 0.9 | 13 |
| 312 | Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016, 35, 102. | 4.9 | 12 |
| 313 | Biomarker in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 156-164. | 1.0 | 35 |
| 314 | Angiogenesis in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 179-181. | 1.0 | 7 |
| 315 | Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer. <i>WJOG</i> 6210G. <i>Cancer Science</i> , 2016, 107, 1843-1850. | 1.7 | 60 |
| 317 | Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors. <i>Targeted Oncology</i> , 2016, 11, 479-487. | 1.7 | 4 |
| 318 | Ramucirumab: Boon or bane. <i>Journal of the Egyptian National Cancer Institute</i> , 2016, 28, 133-140. | 0.6 | 9 |
| 319 | International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1153-1169. | 0.5 | 9 |
| 320 | The safety of monoclonal antibodies for treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 799-808. | 1.0 | 24 |
| 322 | Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. <i>Investigational New Drugs</i> , 2016, 34, 96-103. | 1.2 | 2 |
| 323 | Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06). <i>Clinical Colorectal Cancer</i> , 2016, 15, 314-320.e2. | 1.0 | 6 |
| 324 | Nanotherapeutics promises for colorectal cancer and pancreatic ductal adenocarcinoma. , 2016, , 147-201. | | 3 |
| 325 | The Economics of Personalized Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 123-129. | 1.0 | 2 |
| 326 | Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 230-242. | 1.4 | 58 |
| 327 | The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 233-244. | 1.1 | 29 |
| 328 | Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 877-885. | 1.3 | 11 |
| 329 | The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 585-595. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 330 | The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. <i>Developmental Cell</i> , 2016, 37, 114-125. | 3.1 | 96 |
| 331 | Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. <i>Annals of Oncology</i> , 2016, 27, 1273-1279. | 0.6 | 65 |
| 332 | Outcome of Molecular Targeted Agents Plus Chemotherapy for Second-Line Therapy of Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Trials. <i>Clinical Colorectal Cancer</i> , 2016, 15, e149-e156. | 1.0 | 8 |
| 334 | Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. <i>Visceral Medicine</i> , 2016, 32, 178-183. | 0.5 | 32 |
| 335 | Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 232-240. | 1.0 | 4 |
| 336 | Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). <i>Investigational New Drugs</i> , 2016, 34, 771-776. | 1.2 | 4 |
| 337 | Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 267-282. | 1.0 | 7 |
| 338 | Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. <i>Annals of Oncology</i> , 2016, 27, 2082-2089. | 0.6 | 56 |
| 339 | Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. <i>Annals of Oncology</i> , 2016, 27, 2046-2052. | 0.6 | 33 |
| 340 | Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism. <i>Clinical Colorectal Cancer</i> , 2016, 15, e229-e234. | 1.0 | 4 |
| 342 | Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter?. <i>Journal of Chemotherapy</i> , 2016, 28, 321-327. | 0.7 | 4 |
| 343 | Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer. <i>Journal of Chemotherapy</i> , 2016, 28, 218-224. | 0.7 | 25 |
| 344 | A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 567-575. | 1.1 | 1 |
| 345 | Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC). <i>Targeted Oncology</i> , 2016, 11, 489-500. | 1.7 | 22 |
| 346 | Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1321-1340. | 1.4 | 17 |
| 347 | Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12532-12537. | 3.3 | 30 |
| 348 | The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066. | 2.0 | 17 |
| 349 | Systemic Therapy for Metastatic Colorectal Cancer. , 2016, , 275-338. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 350 | Chemotherapy Maintenance. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 199-204. | 1.0 | 31 |
| 351 | Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2016, 95, e4183. | 0.4 | 11 |
| 352 | Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab. <i>Medicine (United States)</i> , 2016, 95, e4232. | 0.4 | 16 |
| 353 | Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. <i>Medicine (United States)</i> , 2016, 95, e4531. | 0.4 | 14 |
| 354 | Value in Colorectal Cancer Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 232-235. | 1.0 | 7 |
| 355 | Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. <i>BMC Palliative Care</i> , 2016, 15, 25. | 0.8 | 7 |
| 356 | Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor. <i>Oncology Letters</i> , 2016, 11, 939-944. | 0.8 | 13 |
| 357 | Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 208-216. | 1.0 | 0 |
| 358 | Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study). <i>Oncology Letters</i> , 2016, 11, 4049-4054. | 0.8 | 7 |
| 359 | Inhibitors of Angiogenesis. <i>Advances in Experimental Medicine and Biology</i> , 2016, 917, 261-285. | 0.8 | 2 |
| 360 | Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. <i>Clinical Colorectal Cancer</i> , 2016, 15, e221-e227. | 1.0 | 9 |
| 361 | Current targeted therapies in the treatment of advanced colorectal cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 276-293. | 1.4 | 72 |
| 362 | Fatal posterior reversible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 806-810. | 0.5 | 13 |
| 364 | Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model. <i>Oncology Reports</i> , 2016, 36, 626-632. | 1.2 | 14 |
| 365 | Therapeutic options in recurrent glioblastoma—An update. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 389-408. | 2.0 | 161 |
| 366 | The state of regional therapy in the management of metastatic colorectal cancer to the liver. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 229-245. | 1.1 | 5 |
| 367 | A novel antimetabolite: TAS-102 for metastatic colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 355-365. | 1.3 | 11 |
| 368 | Ten years of anti-vascular endothelial growth factor therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 385-403. | 21.5 | 724 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 369 | Current and advancing treatments for metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 93-110. | 1.4 | 31 |
| 370 | Regorafenib in the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 137-145. | 0.9 | 10 |
| 371 | Survival benefit of repeat resection of successive recurrences after the initial hepatic resection for colorectal liver metastases. <i>Surgery</i> , 2016, 159, 632-640. | 1.0 | 58 |
| 372 | Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 557-571. | 1.1 | 7 |
| 373 | Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer. <i>European Journal of Cancer</i> , 2016, 58, 30-37. | 1.3 | 29 |
| 374 | Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. <i>Annals of Oncology</i> , 2016, 27, 1055-1061. | 0.6 | 73 |
| 375 | Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 449-456. | 1.5 | 7 |
| 376 | Antiangiogenic therapy in oncology: current status and future directions. <i>Lancet, The</i> , 2016, 388, 518-529. | 6.3 | 663 |
| 377 | Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3037-3047. | 3.2 | 56 |
| 378 | Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. <i>Targeted Oncology</i> , 2016, 11, 383-400. | 1.7 | 40 |
| 379 | Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 99-106. | 2.0 | 11 |
| 380 | S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). <i>International Journal of Clinical Oncology</i> , 2016, 21, 705-712. | 1.0 | 7 |
| 381 | Pharmacologic resistance in colorectal cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 57-84. | 1.4 | 385 |
| 382 | Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 82-88. | 0.6 | 15 |
| 383 | The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials. <i>Clinical Drug Investigation</i> , 2016, 36, 27-39. | 1.1 | 10 |
| 384 | Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 335-348. | 2.0 | 22 |
| 385 | A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). <i>International Journal of Clinical Oncology</i> , 2016, 21, 335-343. | 1.0 | 10 |
| 386 | Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). <i>International Journal of Clinical Oncology</i> , 2016, 21, 110-117. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 387 | Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. Neuro-Oncology Practice, 2017, 4, 15-23. | 1.0 | 6 |
| 388 | Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer. Breast Cancer, 2017, 24, 147-151. | 1.3 | 4 |
| 389 | Antibodies for Treatment of Metastatic Colorectal Cancer. , 2017, , 217-244. | | 0 |
| 390 | Immunomodulatory Activity of VEGF in Cancer. International Review of Cell and Molecular Biology, 2017, 330, 295-342. | 1.6 | 153 |
| 391 | Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. Cancer Treatment and Research Communications, 2017, 10, 21-26. | 0.7 | 17 |
| 392 | Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. British Journal of Cancer, 2017, 116, 318-323. | 2.9 | 29 |
| 393 | Antiangiogenic Therapy for Malignant Gliomas. , 2017, , 163-175. | | 0 |
| 394 | New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics, 2017, 14, 321-332. | 2.1 | 91 |
| 395 | Second-line systemic therapy for metastatic colorectal cancer. The Cochrane Library, 2017, 1, CD006875. | 1.5 | 26 |
| 396 | Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172. | | 22 |
| 397 | Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs and Aging, 2017, 34, 173-189. | 1.3 | 5 |
| 398 | Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. Cancer Chemotherapy and Pharmacology, 2017, 79, 579-585. | 1.1 | 13 |
| 399 | Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist, 2017, 22, 375-e30. | 1.9 | 25 |
| 400 | The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. European Journal of Cancer, 2017, 75, 245-258. | 1.3 | 82 |
| 401 | HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF. Clinical Colorectal Cancer, 2017, 16, e147-e152. | 1.0 | 32 |
| 403 | Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. European Journal of Cancer, 2017, 78, 7-15. | 1.3 | 42 |
| 404 | Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2017, , 1-16. | | 0 |
| 405 | Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial. Neuro-Oncology Practice, 2017, 4, 171-181. | 1.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 406 | Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392. | 3.8 | 670 |
| 407 | MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. <i>Oncology Letters</i> , 2017, 14, 743-750. | 0.8 | 26 |
| 408 | Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 370-398. | 2.3 | 707 |
| 410 | Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 59-66. | 2.0 | 19 |
| 411 | Revision of the concept of anti-angiogenesis and its applications in tumor treatment. <i>Chronic Diseases and Translational Medicine</i> , 2017, 3, 33-40. | 0.9 | 39 |
| 412 | Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated <i>KRAS</i> . <i>Investigational New Drugs</i> , 2017, 35, 491-498. | 1.2 | 7 |
| 413 | Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017, 77, 13-20. | 1.3 | 19 |
| 414 | Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47. | | 89 |
| 416 | Current Trends in Cancer Therapy. , 2017, , 1-24. | | 7 |
| 417 | Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point. <i>Clinical Therapeutics</i> , 2017, 39, 2135-2145. | 1.1 | 12 |
| 418 | Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer. <i>Oncology</i> , 2017, 93, 191-196. | 0.9 | 3 |
| 419 | Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). <i>Lung Cancer</i> , 2017, 113, 79-84. | 0.9 | 12 |
| 420 | Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1295-1305. | 1.9 | 5 |
| 421 | <i>KRAS</i> mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stage IV colorectal cancer patients. <i>Scientific Reports</i> , 2017, 7, 14368. | 1.6 | 13 |
| 423 | Second-Line Therapy for Advanced Colorectal Cancer: EGFR vs. Continuation of VEGF Inhibition. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 411-418. | 1.0 | 0 |
| 424 | First-line treatment in metastatic colorectal cancer: Important or crucial?. <i>European Journal of Cancer</i> , 2017, 84, 363-366. | 1.3 | 4 |
| 425 | Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study. <i>Scientific Reports</i> , 2017, 7, 13208. | 1.6 | 35 |
| 426 | Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling. <i>Organogenesis</i> , 2017, 13, 183-191. | 0.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 427 | Therapeutic Implications of Angiogenesis in Cancer. , 2017, , 171-216. | | 0 |
| 428 | Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20,000 Patients. Journal of the American Heart Association, 2017, 6, . | 1.6 | 125 |
| 429 | Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Scientific Reports, 2017, 7, 10426. | 1.6 | 8 |
| 430 | Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?. Cancer Chemotherapy and Pharmacology, 2017, 80, 661-671. | 1.1 | 6 |
| 431 | Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data. Tumor Biology, 2017, 39, 101042831771489. | 0.8 | 4 |
| 432 | Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging. Angiogenesis, 2017, 20, 547-555. | 3.7 | 26 |
| 433 | Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. European Journal of Cancer, 2017, 83, 106-115. | 1.3 | 25 |
| 434 | Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Multidisciplinary Management. Colorectal Disease, 2017, 19, 37-66. | 0.7 | 77 |
| 435 | Oral versus intravenous fluoropyrimidines for colorectal cancer. The Cochrane Library, 2017, 2017, CD008398. | 1.5 | 23 |
| 436 | Current Therapies and Future Directions in Treatment of Glioblastoma. Current Cancer Research, 2017, , 57-89. | 0.2 | 1 |
| 437 | TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncology, The, 2017, 18, 1172-1181. | 5.1 | 111 |
| 438 | Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer - A definite conclusion?. Seminars in Oncology, 2017, 44, 129-131. | 0.8 | 3 |
| 439 | Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open, 2017, 2, e000147. | 2.0 | 36 |
| 440 | European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open, 2017, 2, e000190. | 2.0 | 13 |
| 441 | Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker. Journal of Pathology: Clinical Research, 2017, 3, 214-224. | 1.3 | 8 |
| 442 | Recent developments in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 551-564. | 1.4 | 82 |
| 443 | Liver Transplantation for Unresectable Disease. , 2017, , 289-299. | | 0 |
| 444 | An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surgical Oncology Clinics of North America, 2017, 26, 667-687. | 0.6 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 445 | Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. <i>Seminars in Oncology</i> , 2017, 44, 114-128. | 0.8 | 14 |
| 446 | Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. <i>Targeted Oncology</i> , 2017, 12, 599-610. | 1.7 | 121 |
| 447 | Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo. <i>International Journal of Oncology</i> , 2018, 52, 127-138. | 1.4 | 60 |
| 448 | Treatment of Recurrent Epithelial Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 243-265. | 0.0 | 0 |
| 449 | Novel Early Phase Clinical Trial Design in Oncology. <i>Pharmaceutical Medicine</i> , 2017, 31, 297-307. | 1.0 | 3 |
| 450 | Treatment of Refractory Colorectal Cancer: Regorafenib vs. TAS-102. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 325-333. | 1.0 | 0 |
| 451 | The potential role of nintedanib in treating colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1153-1162. | 0.9 | 15 |
| 452 | Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer. <i>Oncology Letters</i> , 2017, 13, 4947-4952. | 0.8 | 4 |
| 453 | Antrodia camphorata inhibits metastasis and epithelial-to-mesenchymal transition via the modulation of claudin-1 and Wnt/ β 2-catenin signaling pathways in human colon cancer cells. <i>Journal of Ethnopharmacology</i> , 2017, 208, 72-83. | 2.0 | 33 |
| 454 | Tumour growth increased following antiangiogenic interruption. <i>Anti-Cancer Drugs</i> , 2017, 28, 1062-1065. | 0.7 | 2 |
| 455 | Protracted inhibition of vascular endothelial growth factor signaling improves survival in metastatic colorectal cancer: A systematic review. <i>Journal of Translational Internal Medicine</i> , 2017, 5, 18-26. | 1.0 | 7 |
| 456 | TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408. | 1.1 | 28 |
| 457 | Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions. <i>Chemotherapy</i> , 2017, 62, 111-120. | 0.8 | 33 |
| 458 | Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer. <i>Radiology</i> , 2017, 282, 443-452. | 3.6 | 25 |
| 459 | Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. <i>Clinical Drug Investigation</i> , 2017, 37, 155-165. | 1.1 | 8 |
| 460 | Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 106-126. | 1.4 | 36 |
| 461 | Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 757-764. | 3.3 | 27 |
| 462 | A Real-World Multicentre Retrospective Study of Paclitaxel+Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 1571-1578. | 2.0 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 463 | Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 9-16. | 1.1 | 12 |
| 464 | Continuum of care strategy in metastatic colorectal cancer: a review. <i>Colorectal Cancer</i> , 2017, 6, 95-103. | 0.8 | 0 |
| 465 | Antiangiogenic therapies in colorectal cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 213-217. | 0.3 | 3 |
| 466 | Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer. <i>ESMO Open</i> , 2017, 2, e000205. | 2.0 | 1 |
| 469 | Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. <i>Frontiers in Pharmacology</i> , 2016, 07, 519. | 1.6 | 59 |
| 470 | Angiogenesis Inhibitors in NSCLC. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2021. | 1.8 | 73 |
| 471 | Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare. <i>Case Reports in Obstetrics and Gynecology</i> , 2017, 2017, 1-4. | 0.2 | 0 |
| 472 | Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. <i>PLoS ONE</i> , 2017, 12, e0183639. | 1.1 | 2 |
| 473 | A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). <i>BMC Cancer</i> , 2017, 17, 499. | 1.1 | 21 |
| 474 | Impact of assay temperature on antibody binding characteristics in living cells: A case study. <i>Biomedical Reports</i> , 2017, 7, 400-406. | 0.9 | 21 |
| 475 | Low-value practices in oncology contributing to financial toxicity. <i>Ecancermedalscience</i> , 2017, 11, 727. | 0.6 | 19 |
| 476 | Anti-VEGF Therapy in Cancer: A Double-Edged Sword. , 0, , . | | 7 |
| 477 | The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy. <i>Journal of Cancer</i> , 2017, 8, 1410-1416. | 1.2 | 6 |
| 478 | Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. <i>Medicine and Pharmacy Reports</i> , 2017, 90, 377-384. | 0.2 | 3 |
| 479 | Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 10703-10713. | 0.8 | 52 |
| 480 | Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil. <i>Cancer Management and Research</i> , 2017, Volume 9, 461-469. | 0.9 | 8 |
| 481 | No benefit from ramucirumab in first-line chemotherapy?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 30-30. | 1.5 | 2 |
| 482 | Targeting the microenvironment in solid tumors. <i>Cancer Treatment Reviews</i> , 2018, 65, 22-32. | 3.4 | 342 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 483 | Discontinuous Schedule of Bevacizumab in Colorectal Cancer Induces Accelerated Tumor Growth and Phenotypic Changes. <i>Translational Oncology</i> , 2018, 11, 406-415. | 1.7 | 20 |
| 484 | Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 809-814. | 1.1 | 7 |
| 485 | Emerging Systemic Therapies for Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2018, 31, 179-191. | 0.5 | 26 |
| 486 | Could New Drugs Offer Opportunities to Extend Resectability in Advanced Presentations?. , 2018, , 307-312. | | 0 |
| 487 | Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San Jos  , Costa Rica, August 2016. <i>ESMO Open</i> , 2018, 3, e000315. | 2.0 | 10 |
| 488 | Recent advances in anti-angiogenic nanomedicines for cancer therapy. <i>Nanoscale</i> , 2018, 10, 5393-5423. | 2.8 | 69 |
| 489 | An Update on Colorectal Cancer. <i>Current Problems in Surgery</i> , 2018, 55, 76-116. | 0.6 | 20 |
| 490 | The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266. | 1.1 | 41 |
| 491 | Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 696-701. | 1.2 | 7 |
| 492 | A safety and immunogenicity study of immunization with hVEGF 26-104 /RFASE in cynomolgus monkeys. <i>Vaccine</i> , 2018, 36, 2025-2032. | 1.7 | 6 |
| 493 | Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 623-629. | 0.9 | 6 |
| 494 | A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e443-e449. | 1.0 | 35 |
| 495 | Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 272 To colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 660-671. | 5.1 | 107 |
| 496 | Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320. | 2.3 | 476 |
| 497 | Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. <i>ESMO Open</i> , 2018, 3, e000297. | 2.0 | 18 |
| 498 | Rapid Development of Omentum Metastasis Following Stereotactic Body Radiotherapy (Sbrt) to Para-Aortic Lymph Nodes from Colon Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 190-194. | 0.6 | 1 |
| 499 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1-34. | 1.0 | 1,187 |
| 500 | A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2018, 23, 25-34. | 1.9 | 63 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 501 | Clinical outcome after biliary drainage for metastatic colorectal cancer: Survival analysis and prognostic factors. <i>Digestive and Liver Disease</i> , 2018, 50, 189-194. | 0.4 | 12 |
| 502 | Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. <i>Targeted Oncology</i> , 2018, 13, 107-112. | 1.7 | 8 |
| 503 | Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. <i>Gut</i> , 2018, 67, 1095-1102. | 6.1 | 19 |
| 504 | Maintenance Chemotherapy for Nonsmall Cell Lung Cancer. , 2018, , 448-465.e4. | | 0 |
| 505 | Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2018, 9, 15-23. | 0.5 | 31 |
| 506 | Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. <i>Seminars in Cancer Biology</i> , 2018, 52, 117-124. | 4.3 | 302 |
| 507 | Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: <sc>A</sc> case report. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 347-351. | 0.6 | 5 |
| 508 | Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0209838. | 1.1 | 6 |
| 509 | A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study. <i>Oncology Letters</i> , 2018, 17, 1980-1985. | 0.8 | 3 |
| 510 | Antiangiogenic Therapy in Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 165-170. | 1.0 | 77 |
| 511 | Laparoscopic posterior pelvic exenteration for primary adenocarcinoma of the rectovaginal septum without associated endometriosis: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 92-96. | 0.4 | 1 |
| 512 | Targeting Angiogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1041-1055. | 0.9 | 11 |
| 513 | Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 359-368. | 0.9 | 8 |
| 514 | Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1716-1724. | 0.8 | 3 |
| 515 | Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 3589-3597. | 0.9 | 7 |
| 516 | Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges. <i>Clinics</i> , 2018, 73, e542s. | 0.6 | 9 |
| 518 | Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practice. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 131, 53-65. | 2.0 | 12 |
| 519 | Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, e183486. | 3.4 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 520 | Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 839-845. | 1.1 | 9 |
| 521 | Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. <i>In Vivo</i> , 2018, 32, 1155-1160. | 0.6 | 5 |
| 522 | Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 883-890. | 1.0 | 5 |
| 523 | Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5059-5074. | 1.0 | 23 |
| 524 | Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. <i>ESMO Open</i> , 2018, 3, e000411. | 2.0 | 13 |
| 525 | Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1487-1491. | 1.0 | 3 |
| 526 | Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab. <i>Neoplasia</i> , 2018, 20, 668-677. | 2.3 | 8 |
| 527 | Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine. <i>Journal of Obstetrics and Gynaecology Research</i> , 2018, 44, 1330-1334. | 0.6 | 9 |
| 528 | ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer. <i>Journal of Biological Chemistry</i> , 2018, 293, 11166-11178. | 1.6 | 50 |
| 529 | Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2018, 5, 9-12. | 1.2 | 7 |
| 530 | Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. <i>Gastrointestinal Tumors</i> , 2018, 5, 38-46. | 0.3 | 8 |
| 531 | Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000375. | 2.0 | 43 |
| 532 | AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e631-e637. | 1.0 | 12 |
| 533 | An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023. <i>BMC Cancer</i> , 2018, 18, 771. | 1.1 | 17 |
| 534 | Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 251-254. | 1.0 | 3 |
| 535 | The safety of ramucirumab for the treatment of colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 945-951. | 1.0 | 14 |
| 536 | Microvessels in the Storm - Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 299. | 1.8 | 29 |
| 537 | Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006. | 1.1 | 44 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 538 | Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 139-149. | 0.4 | 23 |
| 539 | Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , 2018, 124, 3118-3126. | 2.0 | 23 |
| 540 | Antiangiogenic therapy: Markers of response, "normalization" and resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 128, 118-129. | 2.0 | 38 |
| 541 | Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis. <i>Rare Tumors</i> , 2019, 11, 203636131882541. | 0.3 | 5 |
| 542 | Editorial on "The AvaALL Randomized Clinical Trial". <i>Journal of Thoracic Disease</i> , 2019, 11, S1237-S1240. | 0.6 | 1 |
| 543 | Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. <i>Cancer</i> , 2019, 125, 4139-4147. | 2.0 | 299 |
| 544 | Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. <i>JAMA Network Open</i> , 2019, 2, e198243. | 2.8 | 25 |
| 545 | ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. <i>Clinical Colorectal Cancer</i> , 2019, 18, 280-291.e5. | 1.0 | 16 |
| 546 | Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). <i>Digestive and Liver Disease</i> , 2019, 51, 1357-1363. | 0.4 | 80 |
| 547 | Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1213-1220. | 0.9 | 10 |
| 549 | Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263. | 1.4 | 29 |
| 550 | Molecular insight of regorafenib treatment for colorectal cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101912. | 3.4 | 109 |
| 551 | Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency. <i>Cancers</i> , 2019, 11, 68. | 1.7 | 78 |
| 552 | How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1189. | 1.7 | 4 |
| 553 | Precision medicine for metastatic colorectal cancer: an evolving era. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 919-931. | 1.4 | 34 |
| 554 | Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. <i>Frontiers in Oncology</i> , 2019, 9, 766. | 1.3 | 18 |
| 555 | Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. <i>Targeted Oncology</i> , 2019, 14, 505-525. | 1.7 | 40 |
| 556 | A New Therapeutic Strategy for Recurrent Ovarian Cancer"Bevacizumab beyond Progressive Disease. <i>Healthcare (Switzerland)</i> , 2019, 7, 109. | 1.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 557 | Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. <i>Cancer Medicine</i> , 2019, 8, 882-889. | 1.3 | 28 |
| 558 | Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors. <i>Translational Oncology</i> , 2019, 12, 404-416. | 1.7 | 16 |
| 559 | Treatment sequencing in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2019, 109, 70-83. | 1.3 | 215 |
| 560 | MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2019, 14, 285-293. | 1.7 | 11 |
| 561 | Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. <i>Journal of Controlled Release</i> , 2019, 307, 108-138. | 4.8 | 49 |
| 562 | Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). <i>Clinical Colorectal Cancer</i> , 2019, 18, 183-191.e3. | 1.0 | 16 |
| 563 | Reduced Frequency and Prognostic Significance of Ring Finger Protein 43 Nucleotide Polymorphisms in a Chinese Colorectal Cancer Cohort. <i>DNA and Cell Biology</i> , 2019, 38, 541-548. | 0.9 | 3 |
| 564 | Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. <i>Oncologist</i> , 2019, 24, e687-e695. | 1.9 | 19 |
| 565 | Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). <i>International Journal of Clinical Oncology</i> , 2019, 24, 1223-1230. | 1.0 | 9 |
| 566 | Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 307-313. | 1.1 | 9 |
| 567 | Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. <i>Digestive and Liver Disease</i> , 2019, 51, 1185-1191. | 0.4 | 2 |
| 568 | Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer. <i>Cancer Medicine</i> , 2019, 8, 3437-3446. | 1.3 | 12 |
| 569 | ³ Deoxy- ³ TM-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1713-1722. | 3.3 | 8 |
| 570 | VEGF in Signaling and Disease: Beyond Discovery and Development. <i>Cell</i> , 2019, 176, 1248-1264. | 13.5 | 1,468 |
| 571 | Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. <i>Tumori</i> , 2019, 105, 243-252. | 0.6 | 2 |
| 572 | Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib " Results of NCI/CTEP Protocol 9048. <i>Kidney Cancer</i> , 2019, 3, 51-61. | 0.2 | 8 |
| 573 | <p>Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1705-1716. | 0.9 | 22 |
| 574 | Efficacy of Second-Line Chemotherapy after a First-Line Triplet in Patients with Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2019, 26, 4217. | 0.9 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 575 | Acute abdominal obstruction: Colon stent or emergency surgery? An evidence-based review. <i>World Journal of Gastrointestinal Endoscopy</i> , 2019, 11, 193-208. | 0.4 | 31 |
| 576 | Ramucirumab: the long and winding road toward being an option for mCRC treatment. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 399-409. | 1.4 | 6 |
| 577 | Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC). <i>Frontiers in Oncology</i> , 2019, 9, 142. | 1.3 | 6 |
| 578 | Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019, 164, 94-105. | 2.0 | 14 |
| 579 | Systemic treatment for metastatic colorectal cancer in the era of precision medicine. <i>Journal of Surgical Oncology</i> , 2019, 119, 564-582. | 0.8 | 55 |
| 580 | Precision treatment in colorectal cancer: Now and the future. <i>JGH Open</i> , 2019, 3, 361-369. | 0.7 | 36 |
| 581 | How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000813. | 2.0 | 49 |
| 582 | Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. <i>Oncologist</i> , 2019, 24, 1469-1478. | 1.9 | 25 |
| 583 | The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. <i>Cells</i> , 2019, 8, 1602. | 1.8 | 24 |
| 584 | Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond. <i>Current Oncology</i> , 2019, 26, 33-42. | 0.9 | 7 |
| 585 | Recent Advances in the Treatment of Colorectal Cancer. , 2019, , . | | 2 |
| 586 | Chemotherapy for Metastatic Colorectal Cancer. , 2019, , 101-111. | | 1 |
| 587 | SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 46-54. | 1.2 | 40 |
| 588 | Biliary duct stenosis after image-guided high-dose-rate interstitial brachytherapy of central and hilar liver tumors. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 265-273. | 1.0 | 10 |
| 589 | Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. <i>Drug Safety</i> , 2019, 42, 159-179. | 1.4 | 18 |
| 590 | Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 508-515. | 1.0 | 15 |
| 591 | Delta tocotrienol in recurrent ovarian cancer. A phase II trial. <i>Pharmacological Research</i> , 2019, 141, 392-396. | 3.1 | 47 |
| 592 | Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA. <i>International Journal of Colorectal Disease</i> , 2019, 34, 581-588. | 1.0 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 593 | Targeting Angiogenesis in Colorectal Carcinoma. <i>Drugs</i> , 2019, 79, 63-74. | 4.9 | 42 |
| 594 | Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 83. | 3.4 | 63 |
| 595 | Immunotherapeutic Approaches in Cancer. , 2019, , 19-44. | | 4 |
| 596 | Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. <i>Future Oncology</i> , 2019, 15, 543-561. | 1.1 | 10 |
| 597 | A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019, 24, 521-528. | 1.9 | 47 |
| 598 | Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 16-22. | 0.6 | 5 |
| 599 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1-42. | 1.0 | 1,123 |
| 600 | Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1731-1741. | 0.8 | 60 |
| 601 | The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 15-22. | 1.4 | 16 |
| 602 | Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 387-400. | 0.6 | 6 |
| 603 | Efficacy and safety of high-dose vs low-dose leucovorin in patients with colorectal cancer: systematic review and meta-analysis. <i>Colorectal Disease</i> , 2020, 22, 6-17. | 0.7 | 4 |
| 604 | A Complete Response Achieved in a Patient with Hepatic Metastasis from Sigmoid Colon Cancer by a Regimen Containing Ramucirumab: a Case Report. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 624-627. | 0.6 | 0 |
| 605 | Efficacy and Safety of Afibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2020, 19, 39-47.e5. | 1.0 | 9 |
| 606 | Therapeutic Targeting of the Colorectal Tumor Stroma. <i>Gastroenterology</i> , 2020, 158, 303-321. | 0.6 | 51 |
| 607 | Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. <i>Annals of Oncology</i> , 2020, 31, 30-40. | 0.6 | 124 |
| 608 | TBX2 Identified as a Potential Predictor of Bone Metastasis in Lung Adenocarcinoma via Integrated Bioinformatics Analyses and Verification of Functional Assay. <i>Journal of Cancer</i> , 2020, 11, 388-402. | 1.2 | 8 |
| 609 | Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study. <i>Oncologist</i> , 2020, 25, e469-e476. | 1.9 | 20 |
| 610 | Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRÓDIGE 71 - (FFCD 1710) phase III study. <i>Digestive and Liver Disease</i> , 2020, 52, 1143-1147. | 0.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 611 | Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G). <i>Targeted Oncology</i> , 2020, 15, 623-633. | 1.7 | 4 |
| 612 | Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma. <i>Medicine (United States)</i> , 2020, 99, e19908. | 0.4 | 3 |
| 613 | Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy. , 2020, , . | | 2 |
| 614 | Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1143-1157. | 2.7 | 19 |
| 616 | Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 1116. | 1.1 | 2 |
| 617 | Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review. <i>Advances in Therapy</i> , 2020, 37, 4233-4248. | 1.3 | 5 |
| 618 | Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITaCa randomized trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093742. | 1.4 | 5 |
| 619 | First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study. <i>Scientific Reports</i> , 2020, 10, 12336. | 1.6 | 7 |
| 620 | Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China. <i>BMC Cancer</i> , 2020, 20, 990. | 1.1 | 8 |
| 621 | Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 1956. | 2.2 | 143 |
| 622 | Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study. <i>Anticancer Research</i> , 2020, 40, 5285-5290. | 0.5 | 3 |
| 623 | Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21598-21608. | 3.3 | 46 |
| 624 | Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5840. | 1.8 | 143 |
| 625 | A narrative review of the role of fibroblasts in the growth and development of neurogenic tumors. <i>Annals of Translational Medicine</i> , 2020, 8, 1462-1462. | 0.7 | 4 |
| 626 | Current Trends in Cancer Immunotherapy. <i>Biomedicines</i> , 2020, 8, 621. | 1.4 | 34 |
| 627 | Recent Developments of Systemic Chemotherapy for Gastric Cancer. <i>Cancers</i> , 2020, 12, 1100. | 1.7 | 31 |
| 628 | Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 â€“ REGOLD. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1255-1262. | 0.5 | 12 |
| 629 | Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1214. | 1.7 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 630 | Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020, 12, 1259. | 1.7 | 19 |
| 631 | Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). <i>Clinical Colorectal Cancer</i> , 2020, 19, 285-290. | 1.0 | 5 |
| 633 | An Animal Model of Colorectal Cancer Liver Metastasis With a High Metastasis Rate and Clonal Dynamics. <i>Anticancer Research</i> , 2020, 40, 3297-3306. | 0.5 | 5 |
| 634 | Maintenance treatment in advanced HER2-negative gastric cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 2206-2212. | 1.2 | 10 |
| 635 | Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2020, 40, 1605-1611. | 0.5 | 3 |
| 636 | Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507. | 5.1 | 196 |
| 637 | The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. <i>PLoS ONE</i> , 2020, 15, e0229900. | 1.1 | 12 |
| 638 | Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675. | 1.0 | 57 |
| 639 | Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270. | 1.1 | 4 |
| 640 | Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091091. | 1.4 | 12 |
| 641 | Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i> -Mutated Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1148-1156. | 1.9 | 22 |
| 642 | Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22. | 7.1 | 853 |
| 643 | Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. <i>Future Oncology</i> , 2020, 16, 225-246. | 1.1 | 63 |
| 644 | Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. <i>Cancers</i> , 2020, 12, 657. | 1.7 | 14 |
| 645 | Rechallenge Strategy in Cancer Therapy. <i>Oncology</i> , 2020, 98, 669-679. | 0.9 | 9 |
| 646 | Dual inhibition of VEGF and PARP suppresses <i>KRAS</i> -mutant colorectal cancer. <i>Neoplasia</i> , 2020, 22, 365-375. | 2.3 | 7 |
| 647 | Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2020, 40, 4157-4163. | 0.5 | 6 |
| 648 | Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. <i>Clinical Therapeutics</i> , 2020, 42, 1361-1375. | 1.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 649 | Skin Toxicities During Colorectal Cancer Chemotherapy: Incidence and Pearls of Treatment in Our Experience. <i>Clinical Colorectal Cancer</i> , 2020, 19, e235-e242. | 1.0 | 4 |
| 650 | A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. <i>Journal of Ovarian Research</i> , 2020, 13, 14. | 1.3 | 9 |
| 651 | The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy. <i>Medicine (United States)</i> , 2020, 99, e19258. | 0.4 | 6 |
| 652 | hERG1 and HIF-2 β Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients. <i>Translational Oncology</i> , 2020, 13, 100740. | 1.7 | 21 |
| 653 | Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. <i>Targeted Oncology</i> , 2020, 15, 193-201. | 1.7 | 4 |
| 654 | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. <i>Cells</i> , 2020, 9, 219. | 1.8 | 46 |
| 655 | Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102877. | 2.0 | 14 |
| 656 | Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data. <i>Statistics in Medicine</i> , 2020, 39, 1103-1124. | 0.8 | 14 |
| 657 | Angiocrine endothelium: from physiology to cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 52. | 1.8 | 53 |
| 658 | Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial. <i>Clinical Therapeutics</i> , 2020, 42, 848-859. | 1.1 | 8 |
| 660 | Traditional Chinese Medicine Combined With Chemotherapy and Cetuximab or Bevacizumab for Metastatic Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Frontiers in Pharmacology</i> , 2020, 11, 478. | 1.6 | 22 |
| 661 | The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020, 12, 1022. | 1.7 | 16 |
| 662 | Bevacizumab (Avastin [®]) in cancer treatment: A review of 15 years of clinical experience and future outlook. <i>Cancer Treatment Reviews</i> , 2020, 86, 102017. | 3.4 | 573 |
| 663 | Orally delivered targeted nanotherapeutics for the treatment of colorectal cancer. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 781-790. | 2.4 | 13 |
| 664 | Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021, 124, 183-190. | 2.9 | 7 |
| 665 | An appraisal of emerging second line therapies for metastatic colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 165-179. | 1.4 | 2 |
| 666 | Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 111-117. | 1.0 | 21 |
| 667 | Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics. <i>Medicinal Research Reviews</i> , 2021, 41, 464-506. | 5.0 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 668 | Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect. <i>Cancer Medicine</i> , 2021, 10, 164-172. | 1.3 | 10 |
| 669 | Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135. | 3.4 | 2 |
| 670 | A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26 ¹⁰⁴ /RFASE in Patients with Advanced Solid Malignancies. <i>Oncologist</i> , 2021, 26, e218-e229. | 1.9 | 4 |
| 671 | Controversies in the treatment of RAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 827-839. | 1.2 | 3 |
| 672 | Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC study (AIO ¹¹¹). <i>International Journal of Cancer</i> , 2021, 148, 1428-1437. | 2.3 | 2 |
| 673 | Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592198922. | 1.4 | 7 |
| 674 | Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial. <i>Journal of Cancer</i> , 2021, 12, 5268-5274. | 1.2 | 3 |
| 675 | Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> . 2021, 33, 490-499. | 0.7 | 5 |
| 676 | Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 605-618. | 1.0 | 14 |
| 677 | Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis. , 2021, , 239-253. | | 0 |
| 678 | Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs (Review). <i>Oncology Letters</i> , 2021, 21, 315. | 0.8 | 8 |
| 679 | Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. <i>Clinical and Translational Oncology</i> , 2021, 23, 1520-1528. | 1.2 | 4 |
| 680 | Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 465-e917. | 1.9 | 13 |
| 681 | Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. <i>PLoS ONE</i> , 2021, 16, e0246160. | 1.1 | 7 |
| 682 | Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. <i>Cancer Cell International</i> , 2021, 21, 83. | 1.8 | 17 |
| 683 | Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 267-276. | 5.1 | 79 |
| 684 | Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial. <i>British Journal of Surgery</i> , 2021, 108, 373-379. | 0.1 | 7 |
| 685 | Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer—the Experience of a Tertiary Cancer Center. <i>Frontiers in Pharmacology</i> , 2021, 12, 487316. | 1.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 686 | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. <i>Frontiers in Oncology</i> , 2021, 11, 589680. | 1.3 | 23 |
| 687 | Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. <i>Cancers</i> , 2021, 13, 1031. | 1.7 | 21 |
| 688 | Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <i>Scientific Reports</i> , 2021, 11, 7118. | 1.6 | 5 |
| 689 | Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries. <i>Frontiers in Oncology</i> , 2021, 11, 630456. | 1.3 | 7 |
| 690 | MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. <i>Biomedicines</i> , 2021, 9, 318. | 1.4 | 7 |
| 691 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359. | 2.3 | 758 |
| 692 | Bevacizumab Combined with Sâ€1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. <i>Oncologist</i> , 2021, 26, e1320-e1326. | 1.9 | 3 |
| 693 | Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). <i>ESMO Open</i> , 2021, 6, 100054. | 2.0 | 7 |
| 694 | Pathological Complete Response to Second Line Chemotherapy in a Patient with Cervical Lymph Node Metastasis from Transverse Colon Cancer with RAS and BRAF V600E Mutations: A Case Report. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 278-284. | 0.0 | 0 |
| 695 | Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. <i>ESMO Open</i> , 2021, 6, 100093. | 2.0 | 11 |
| 696 | Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 295-304. | 0.8 | 1 |
| 697 | Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 637823. | 1.3 | 8 |
| 698 | Hepatic Arterial Infusion Pumps: What the Radiologist Needs to Know. <i>Radiographics</i> , 2021, 41, 895-908. | 1.4 | 4 |
| 699 | Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies. <i>Gastroenterology</i> , 2021, 160, 1947-1960. | 0.6 | 42 |
| 700 | Modeling adaptive drug resistance of colorectal cancer and therapeutic interventions with tumor spheroids. <i>Experimental Biology and Medicine</i> , 2021, 246, 2372-2380. | 1.1 | 3 |
| 701 | Up-to-date role of aflibercept in the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1315-1324. | 1.4 | 2 |
| 702 | Riskâ€benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2021, 41, 3091-3097. | 0.5 | 0 |
| 703 | Treatment sequencing of metastatic colorectal cancer based on primary tumor location. <i>Seminars in Oncology</i> , 2021, 48, 119-129. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 704 | Targeted agents in older patients with gastrointestinal cancers – An overview. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1240-1252. | 0.5 | 0 |
| 705 | Lactate Dehydrogenase Is a Useful Marker for Predicting the Efficacy of Bevacizumab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2021, 41, 3535-3542. | 0.5 | 1 |
| 706 | Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7717. | 1.8 | 7 |
| 707 | Colorectal Cancer: From Genetic Landscape to Targeted Therapy. <i>Journal of Oncology</i> , 2021, 2021, 1-17. | 0.6 | 28 |
| 708 | Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2022, 34, 221-234. | 0.7 | 3 |
| 709 | Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience. <i>Cancers</i> , 2021, 13, 3863. | 1.7 | 6 |
| 710 | Clinicopathological and prognostic significance of LINC00673 in human malignancy: a review and meta-analysis. <i>Bioscience Reports</i> , 2021, 41, . | 1.1 | 1 |
| 711 | The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1407-1415. | 0.6 | 0 |
| 712 | The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1721-1735. | 1.2 | 3 |
| 713 | FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 3151-3162. | 1.1 | 14 |
| 714 | <i>KRAS</i> mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1325-1334. | 1.4 | 4 |
| 715 | Impact of <i>UGT1A1</i> genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 4669-4678. | 1.7 | 8 |
| 716 | Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab. <i>Oncology Letters</i> , 2021, 22, 783. | 0.8 | 7 |
| 717 | miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1263-1273. | 0.4 | 4 |
| 718 | Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. <i>Clinical Colorectal Cancer</i> , 2021, 20, e173-e184. | 1.0 | 7 |
| 719 | Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. <i>Clinical Colorectal Cancer</i> , 2021, 20, 245-255. | 1.0 | 2 |
| 720 | Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111827. | 2.5 | 3 |
| 721 | Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study. <i>ESMO Open</i> , 2021, 6, 100270. | 2.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 722 | Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. <i>European Journal of Cancer</i> , 2021, 157, 153-164. | 1.3 | 10 |
| 723 | Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept. <i>Anticancer Research</i> , 2021, 41, 533-541. | 0.5 | 3 |
| 724 | Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. <i>Cancer Medicine</i> , 2021, 10, 615-625. | 1.3 | 10 |
| 726 | Essentials of Angiogenesis. , 2015, , 137-165. | | 1 |
| 727 | Prolonged clinical response with regorafenib administered as second-line therapy in an elderly patient suffering from peritoneal carcinomatosis of colon cancer. <i>Journal of Chemotherapy</i> , 2021, 33, 187-192. | 0.7 | 1 |
| 728 | Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024. | 3.2 | 22 |
| 729 | Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. <i>Cancer Discovery</i> , 2021, 11, 308-325. | 7.7 | 49 |
| 730 | EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. <i>JCI Insight</i> , 2019, 4, . | 2.3 | 88 |
| 731 | FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016, 126, 1885-1896. | 3.9 | 101 |
| 732 | Clinicopathological differences and correlations between right and left colon cancer. <i>World Journal of Clinical Cases</i> , 2020, 8, 1424-1443. | 0.3 | 16 |
| 733 | An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e89960. | 1.1 | 27 |
| 734 | Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab. <i>PLoS ONE</i> , 2014, 9, e109430. | 1.1 | 39 |
| 735 | Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0145004. | 1.1 | 20 |
| 736 | Antiangiogenic Therapy for Glioblastoma: The Challenge of Translating Response Rate into Efficacy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e71-e78. | 1.8 | 5 |
| 737 | Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature. <i>Medicine and Pharmacy Reports</i> , 2018, 91, 12-17. | 0.2 | 10 |
| 738 | Liver transplantation for metastatic colorectal cancer (case report). <i>Annals of HPB Surgery</i> , 2019, 23, 54-67. | 0.1 | 3 |
| 739 | Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. <i>Oncotarget</i> , 2016, 7, 50656-50665. | 0.8 | 39 |
| 740 | Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 36707-36715. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 741 | NHERF1 regulates the progression of colorectal cancer through the interplay with VEGFR2 pathway. <i>Oncotarget</i> , 2017, 8, 7753-7765. | 0.8 | 6 |
| 742 | Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. <i>Oncotarget</i> , 2017, 8, 51492-51506. | 0.8 | 38 |
| 743 | Oncolytic reovirus preferentially induces apoptosis in <i>KRAS</i> mutant colorectal cancer cells, and synergizes with irinotecan. <i>Oncotarget</i> , 2014, 5, 2807-2819. | 0.8 | 43 |
| 744 | Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. <i>Oncotarget</i> , 2017, 8, 101383-101393. | 0.8 | 31 |
| 745 | Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). <i>Oncotarget</i> , 2017, 8, 105749-105760. | 0.8 | 41 |
| 746 | Changes in expression levels of <i>ERCC1</i> , <i>DPYD</i> , and <i>VEGFA</i> mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. <i>Oncotarget</i> , 2015, 6, 34004-34013. | 0.8 | 13 |
| 747 | Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?. <i>Oncotarget</i> , 2016, 7, 9309-9321. | 0.8 | 30 |
| 748 | Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. <i>Oncotarget</i> , 2016, 7, 11380-11396. | 0.8 | 12 |
| 749 | Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 46678-46691. | 0.8 | 35 |
| 750 | Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016, 7, 35132-35143. | 0.8 | 9 |
| 751 | Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 614-624. | 0.6 | 41 |
| 752 | CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. <i>Current Pharmaceutical Design</i> , 2015, 21, 2276-2283. | 0.9 | 15 |
| 753 | Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2019, 21, 718-724. | 0.6 | 12 |
| 754 | Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. <i>Current Drug Targets</i> , 2016, 18, 56-71. | 1.0 | 25 |
| 755 | Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 6431-6438. | 0.5 | 21 |
| 756 | Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2017, 37, 6459-6468. | 0.5 | 8 |
| 757 | Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis. <i>Ecancermedicalscience</i> , 2020, 14, 1069. | 0.6 | 15 |
| 758 | Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 8474. | 1.4 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 759 | Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 6102. | 1.4 | 45 |
| 760 | Personalizing medicine for metastatic colorectal cancer: Current developments. <i>World Journal of Gastroenterology</i> , 2014, 20, 10425. | 1.4 | 12 |
| 761 | How to select the optimal treatment for first line metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 899. | 1.4 | 31 |
| 762 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. <i>World Journal of Gastroenterology</i> , 2015, 21, 5352. | 1.4 | 5 |
| 763 | Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. <i>World Journal of Gastroenterology</i> , 2015, 21, 7281-7288. | 1.4 | 10 |
| 764 | Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases. <i>World Journal of Gastroenterology</i> , 2016, 22, 3127. | 1.4 | 34 |
| 765 | Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1188-1196. | 0.7 | 3 |
| 766 | Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 231-8. | 0.6 | 18 |
| 767 | Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 134-42. | 0.6 | 81 |
| 768 | Review of systemic therapies for locally advanced and metastatic rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 185-200. | 0.6 | 45 |
| 769 | Meta-analysis of molecular targeted agents in the treatment of elderly patients with metastatic colorectal cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, S79-S84. | 0.3 | 8 |
| 770 | Metastatic colorectal cancer-prolonging overall survival with targeted therapies. <i>South Asian Journal of Cancer</i> , 2013, 2, 179. | 0.2 | 25 |
| 771 | Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017, 49, 834-845. | 1.3 | 12 |
| 772 | Anti-angiogenic agents in metastatic colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 71. | 0.8 | 22 |
| 773 | Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy. <i>World Journal of Clinical Oncology</i> , 2019, 10, 52-61. | 0.9 | 17 |
| 774 | Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2019, 10, 75-85. | 0.9 | 7 |
| 775 | FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2018, 9, 110-118. | 0.9 | 9 |
| 776 | Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6559-6564. | 0.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 777 | Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 5119-5127. | 1.1 | 9 |
| 778 | Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 131. | 1.0 | 0 |
| 779 | Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. <i>Clinical Colorectal Cancer</i> , 2022, 21, e49-e61. | 1.0 | 5 |
| 780 | Bevacizumab Combination Chemotherapy in Clinical Practice for Advanced Non-squamous Non-small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2013, 53, 215-219. | 0.0 | 0 |
| 781 | Locus Chemotherapy in Cancer Angiogenesis. <i>Biological Systems, Open Access</i> , 2013, 02, . | 0.1 | 0 |
| 782 | The factors for prolonging the prognosis in Sorafenib therapy for hepatocellular carcinoma with extrahepatic metastasis. <i>Acta Hepatologica Japonica</i> , 2013, 54, 563-566. | 0.0 | 0 |
| 783 | Molecular targeted therapies and gastroenterological neoplasia. <i>Okayama Igakkai Zasshi</i> , 2013, 125, 145-152. | 0.0 | 0 |
| 784 | Indications et gestion des effets secondaires. , 2013, , 209-222. | | 0 |
| 785 | Essentials of Angiogenesis. , 2014, , 1-34. | | 1 |
| 786 | Bevacizumab in Combination with FOLFIRI in the First-Line Treatment of Patients with Advanced Colorectal Cancer: A Single- Institution Experience. <i>Journal of Analytical Oncology</i> , 0, , . | 0.1 | 0 |
| 787 | Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies. <i>World Journal of Gastroenterology</i> , 2014, 20, 10288. | 1.4 | 3 |
| 788 | Bevacizumab maintenance in metastatic colorectal cancer: How long?. <i>World Journal of Clinical Cases</i> , 2014, 2, 717. | 0.3 | 0 |
| 789 | Advances in the Medical Management of Ovarian Cancer. , 2014, , 77-107. | | 0 |
| 790 | Metastatic Rectal Cancer. , 2015, , 287-310. | | 0 |
| 791 | Targeted Therapies For Intestinal Tumorigenesis. , 2015, , 391-440. | | 0 |
| 792 | Targeted Therapies for Colorectal Cancer. <i>Current Clinical Pathology</i> , 2015, , 147-162. | 0.0 | 0 |
| 793 | Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective Analysis. <i>Advances in Lung Cancer (Irvine)</i> , 2015, 04, 8-15. | 0.2 | 0 |
| 794 | Adverse Effects of Bevacizumab During Treatment for Metastatic Colorectal Cancer. <i>Journal of Analytical Oncology</i> , 2015, 4, 24-29. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 795 | VEGFA and PlGF Protein Signature of Primary Stage IV Rectal Cancer Pre and Post Neoadjuvant Radiotherapy, Bevacizumab, and Chemotherapy. <i>Current Angiogenesis</i> , 2015, 3, 164-173. | 0.1 | 0 |
| 796 | Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. <i>Cancer Treatment and Research</i> , 2016, 168, 393-479. | 0.2 | 0 |
| 797 | Colorectal and Anal Tumors. <i>Pediatric Oncology</i> , 2017, , 319-333. | 0.5 | 0 |
| 798 | Cancer Drug Delivery. , 2017, , 185-228. | | 0 |
| 799 | Systemic chemotherapy for hepatic colorectal cancer. , 2017, , 1488-1501.e5. | | 0 |
| 800 | Unresectable colorectal cancer liver metastases treated with radioembolization: Updated survival analysis of the MORE study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 666-666. | 0.8 | 0 |
| 801 | Safety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study. <i>PLoS ONE</i> , 2017, 12, e0176899. | 1.1 | 2 |
| 803 | Molecularly Targeted Therapies in Pancreatic Cancer. , 2018, , 219-233. | | 0 |
| 804 | Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC). <i>Anticancer Research</i> , 2017, 37, 3771-3779. | 0.5 | 2 |
| 805 | The application of the modern target medications for the treatment of metastatic colorectal cancer. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2018, 7, 21. | 0.3 | 1 |
| 806 | Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. , 2018, , 245-260. | | 0 |
| 807 | Second-Line Chemotherapy in Colorectal Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2018, 71, 380-386. | 0.1 | 0 |
| 808 | OPTIMAL SEQUENCES AND COMBINATION OF CHEMOTHERAPY AND MONOCLONAL ANTIBODIES IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER. <i>Malignant Tumours</i> , 2018, 8, 50-59. | 0.1 | 2 |
| 809 | Intensification thérapeutique dans la prise en charge du cancer colorectal métastatique : trichimiothérapie systémique et traitements intra-artériels hépatiques. <i>Colon and Rectum</i> , 2018, 12, 170-177. | 0.0 | 0 |
| 810 | Traitement du cancer colorectal métastatique : ciblage moléculaire. <i>Colon and Rectum</i> , 2018, 12, 178-183. | 0.0 | 0 |
| 811 | Molecular Target Therapy for Digestive Malignancy. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2018, 14, 169-172. | 0.0 | 0 |
| 812 | Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy. , 2019, , 379-394. | | 0 |
| 813 | Metastatic Colorectal Cancer. , 2019, , 135-160. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 814 | An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness. <i>Translational Cancer Research</i> , 2019, 8, 2357-2370. | 0.4 | 1 |
| 815 | Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims. <i>Current Cancer Therapy Reviews</i> , 2019, 15, 184-191. | 0.2 | 0 |
| 816 | Sequencing of Systemic Chemotherapy for Unresectable CRLM. , 2020, , 297-312. | | 0 |
| 817 | Liver Transplantation for CRLM—Is It Ever Indicated?. , 2020, , 531-546. | | 0 |
| 818 | Current perspective on the treatment of advanced/metastatic colorectal cancer. <i>Onkologie (Czech) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i> | 0.0 | 0 |
| 819 | Risk of Hypertension Associated with Antivascular Endothelial Growth Factor Monoclonal Antibodies: A Meta-Analysis From 51088 Patients with Cancer. <i>Iranian Red Crescent Medical Journal</i> , 2020, 22, . | 0.5 | 2 |
| 820 | Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023. <i>Cancer Science</i> , 2022, 113, 240-250. | 1.7 | 17 |
| 821 | The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2021, , . | 2.9 | 3 |
| 822 | Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 1159. | 1.1 | 5 |
| 823 | Current Status of Adjuvant Therapy for Glioblastoma and Potential Novel Therapies. <i>Japanese Journal of Neurosurgery</i> , 2020, 29, 188-197. | 0.0 | 0 |
| 824 | Correlation of Bevacizumab-induced Proteinuria with Therapeutic Effects in Patients with Colorectal Cancer. <i>Korean Journal of Clinical Pharmacy</i> , 2020, 30, 234-242. | 0.0 | 0 |
| 825 | Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48. | | 0 |
| 826 | Optimal Sequence and Second-Line Systemic Treatment of Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5166. | 1.0 | 2 |
| 827 | Cancer Drug Delivery. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 0, , 52-95. | 0.3 | 0 |
| 828 | Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, S11-20. | 0.6 | 7 |
| 829 | Targeted therapies in colorectal cancer: the dos, don'ts, and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 239-44. | 0.6 | 0 |
| 830 | Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 299-307. | 0.6 | 6 |
| 831 | Status of targeted therapies in the adjuvant treatment of colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 245-52. | 0.6 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 832 | Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 99-103. | 0.6 | 4 |
| 833 | Which strategy after first-line therapy in advanced colorectal cancer?. <i>World Journal of Gastroenterology</i> , 2014, 20, 8921-7. | 1.4 | 3 |
| 834 | Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 1434-45. | 1.3 | 10 |
| 835 | Saudi Oncology Society clinical management guideline series. Colorectal cancer 2014. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2014, 35, 1538-44. | 0.5 | 5 |
| 836 | Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>American Health and Drug Benefits</i> , 2016, 9, 221-32. | 0.5 | 19 |
| 838 | Analysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1368. | 0.7 | 1 |
| 839 | Personalized medicine in colorectal cancer. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2020, 13, S18-S28. | 0.6 | 1 |
| 840 | Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia. <i>Value in Health Regional Issues</i> , 2022, 28, 67-75. | 0.5 | 1 |
| 841 | Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 754858. | 1.6 | 2 |
| 842 | Combined Primary Resection with Hepatic Artery Infusion Pump Implantation Is Safe for Unresectable Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 764-771. | 0.9 | 5 |
| 843 | Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 715-734. | 1.6 | 6 |
| 844 | Analysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1368-1368. | 0.7 | 3 |
| 845 | Is there an efficacy-effectiveness gap between randomized controlled trials and real-world studies in colorectal cancer: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 6963-6987. | 0.4 | 4 |
| 847 | Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 589-597. | 1.0 | 6 |
| 848 | Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy. <i>Annals of Surgical Oncology</i> , 2022, 29, 3938-3949. | 0.7 | 2 |
| 849 | Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. <i>Oncologist</i> , 2022, 27, 292-298. | 1.9 | 2 |
| 850 | Precision medicine for metastatic colorectal cancer in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110727. | 1.4 | 23 |
| 851 | Antiangiogenic drugs: Chemosensitizers for combination cancer therapy. , 2022, , 29-66. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-------|-----------|
| 852 | Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996. | 4.3 | 15 |
| 853 | Treatment of metastatic colorectal cancer in the year 2020. <i>Onkologie (Czech Republic)</i> , 2021, 14, 258-261. | 0.0 | 0 |
| 854 | Efficacy of Gemcitabine and Bevacizumab Combination Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Analysis. <i>Journal of St Marianna University</i> , 2021, 12, 69-75. | 0.1 | 0 |
| 855 | The sequence of antiVEGF(R) preparations in the treatment of metastatic colorectal carcinoma in 2020. <i>Onkologie (Czech Republic)</i> , 2021, 14, 263-267. | 0.0 | 0 |
| 857 | Comparison of <i>UGT1A1</i> Polymorphism as Guidance of Irinotecan Dose Escalation in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy. <i>Oncology Research</i> , 2022, 29, 47-61. | 0.6 | 8 |
| 858 | Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial. <i>Cancer Control</i> , 2022, 29, 107327482210803. | 0.7 | 0 |
| 859 | HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by regulating myeloid-derived suppressor cells. <i>Cancer Cell International</i> , 2022, 22, 88. | 1.8 | 6 |
| 860 | Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer. <i>Journal of the Formosan Medical Association</i> , 2022, , . | 0.8 | 3 |
| 861 | Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1. | 1.2 | 0 |
| 862 | Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second-line therapy for metastatic colon cancer: a retrospective multicenter study. <i>Pelvic Surgery and Oncology</i> , 2022, 11, 11-17. | 0.2 | 0 |
| 863 | Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 798-808. | 0.7 | 2 |
| 864 | Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer. <i>Advances in Therapy</i> , 2022, , 1. | 1.3 | 3 |
| 865 | Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers. <i>ESMO Open</i> , 2022, 7, 100417. | 2.0 | 3 |
| 866 | Advances in liver transplantation for unresectable colon cancer liver metastasis. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 1615-1627. | 0.8 | 0 |
| 876 | Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 771-785. | 0.3 | 1 |
| 877 | Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen. <i>Anticancer Research</i> , 2022, 42, 2675-2681. | 0.5 | 0 |
| 878 | Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401. | 157.7 | 167 |
| 879 | The roles and limitations of bevacizumab in the treatment of ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1120-1126. | 1.0 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 880 | Ligustilide Inhibits Tumor Angiogenesis by Downregulating VEGFA Secretion from Cancer-Associated Fibroblasts in Prostate Cancer via TLR4. <i>Cancers</i> , 2022, 14, 2406. | 1.7 | 11 |
| 881 | Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?. <i>Frontiers in Oncology</i> , 2022, 12, . | 1.3 | 1 |
| 882 | Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 170, 64-72. | 1.3 | 3 |
| 883 | Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 1 |
| 884 | Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. <i>International Journal of Cancer</i> , 2022, 151, 2172-2181. | 2.3 | 2 |
| 885 | FOLFIRI plus BEvacizumab or aflibercept after FOLFOX in bevacizumab failure for colorectal cancer (BEFLICO): An AGEO multicenter study. <i>International Journal of Cancer</i> , 2022, 151, 1978-1988. | 2.3 | 5 |
| 886 | ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 1 |
| 887 | Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01). <i>Clinical and Translational Oncology</i> , 2022, 24, 2155-2165. | 1.2 | 6 |
| 888 | The emerging era of personalized medicine in advanced colorectal cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1411-1425. | 1.4 | 6 |
| 889 | Immunotherapy and targeted therapies for colorectal liver metastasis. , 2023, , 231-246. | | 0 |
| 890 | Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study. <i>Cancers</i> , 2022, 14, 3522. | 1.7 | 2 |
| 891 | Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. <i>International Journal of Clinical Oncology</i> , 0, . | 1.0 | 0 |
| 892 | Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study. <i>Oncology Research and Treatment</i> , 2022, 45, 576-587. | 0.8 | 2 |
| 893 | Efficacy and safety of dilpacicab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. <i>Future Oncology</i> , 2022, 18, 3011-3020. | 1.1 | 5 |
| 894 | The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, . | 1.2 | 3 |
| 895 | Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). <i>ESMO Open</i> , 2022, 7, 100567. | 2.0 | 9 |
| 896 | Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 347. | 0.3 | 2 |
| 897 | Sesamin inhibits hypoxia-stimulated angiogenesis via the NF- κ B p65/HIF-1 α /VEGFA signaling pathway in human colorectal cancer. <i>Food and Function</i> , 2022, 13, 8989-8997. | 2.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 898 | Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 4 |
| 899 | Effect of vitamins C and E on cancer survival; a systematic review. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2022, 30, 427-441. | 0.9 | 3 |
| 900 | Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1579-1589. | 0.9 | 5 |
| 901 | A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 2 |
| 902 | Circulating vascular endothelial growth factor and cancer risk: A bidirectional mendelian randomization. <i>Frontiers in Genetics</i> , 0, 13, . | 1.1 | 3 |
| 903 | Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study). <i>International Journal of Clinical Oncology</i> , 2022, 27, 1859-1866. | 1.0 | 3 |
| 904 | The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer. <i>Life</i> , 2022, 12, 1552. | 1.1 | 0 |
| 905 | Screening ssDNA Aptamers Against Human Vascular Endothelial Factor 165 via Semirational Design. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 4983-4991. | 2.5 | 0 |
| 906 | Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 2 |
| 907 | Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 909 | Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 10-32. | 0.6 | 316 |
| 910 | Colorectal Cancer Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2023, 32, 119-141. | 0.6 | 7 |
| 911 | Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. <i>European Journal of Cancer</i> , 2023, 178, 162-170. | 1.3 | 1 |
| 912 | The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status. <i>Cancers</i> , 2022, 14, 5391. | 1.7 | 1 |
| 913 | Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study. <i>Cancers</i> , 2022, 14, 5522. | 1.7 | 3 |
| 914 | Biomarkers for anti-vascular endothelial growth factor drugs. <i>Oncology Letters</i> , 2022, 24, . | 0.8 | 2 |
| 915 | Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 916 | Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment. <i>Cancer Treatment and Research Communications</i> , 2023, 34, 100674. | 0.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 917 | Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond. , 2022, , 293-299. | | 0 |
| 918 | Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292. | | 0 |
| 919 | Current Targeted Therapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 1702. | 1.8 | 22 |
| 920 | Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study. ESMO Open, 2023, 8, 100748. | 2.0 | 0 |
| 921 | Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 755-767. | 1.5 | 3 |
| 923 | New developments in targeted therapy for metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211485. | 1.4 | 8 |
| 924 | Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials. Cancers, 2023, 15, 2117. | 1.7 | 4 |
| 925 | Natural Compounds Targeting the Autophagy Pathway in the Treatment of Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 7310. | 1.8 | 4 |
| 926 | A Patient with Transverse Colon Cancer Complicated by Cowden Syndrome Administered FOLFOXIRI + Bevacizumab Therapy. Case Reports in Gastroenterology, 2023, 17, 62-69. | 0.3 | 0 |
| 927 | Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study. Clinical and Experimental Medicine, 0, , . | 1.9 | 0 |
| 928 | Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice. Medicina (Lithuania), 2023, 59, 350. | 0.8 | 3 |
| 930 | CACA guidelines for holistic integrative management of rectal cancer. , 2023, 2, . | | 0 |
| 931 | Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World Journal of Gastroenterology, 0, 29, 1395-1426. | 1.4 | 8 |
| 932 | Real-world Efficacy Data on Anti-Angiogenic Drugs in Recurrent Small Cell Cervical Carcinoma: A Retrospective Study. Technology in Cancer Research and Treatment, 2023, 22, 153303382311603. | 0.8 | 1 |
| 933 | SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation. Future Oncology, 0, , . | 1.1 | 0 |
| 934 | Systemic treatment for metastatic colorectal cancer. World Journal of Gastroenterology, 0, 29, 1425-1444. | 1.4 | 0 |
| 935 | Systemic treatment for metastatic colorectal cancer. World Journal of Gastroenterology, 0, 29, 1569-1588. | 1.4 | 8 |
| 936 | Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer. Cancer Management and Research, 0, Volume 15, 277-289. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 937 | Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. ACS Pharmacology and Translational Science, 2023, 6, 710-726. | 2.5 | 2 |
| 939 | A review on emerging targeted therapies for the management of metastatic colorectal cancers. , 2023, 40, . | | 6 |
| 968 | Colorectal cancer heterogeneity and targeted therapy: clinical implications, challenges, and solutions for treatment resistance. , 2023, , 207-221. | | 0 |